As of recently, four different brands of COVID-19 vaccines were in production and use. Pfizer, Moderna, Johnson and Johnson, and AstraZeneca have been injected into the arms of people 16 years and older for a couple weeks now.

In the past week, it has been announced that the Johnson and Johnson vaccine’s production will be halted for the time being while scientists research a rare condition caused by the vaccine. Seven young women in the United States have developed blood clots after receiving the single shot vaccine. About 7 million people had received the jab prior to this announcement, so the chance of getting this condition is about 1 in a million at the current standings. However, it’s enough of a prevalence that scientists want to pull it off of the technical market, especially since one of the cases has recently resulted in the passing of one of the women.

Another recent announcement was by the CEO of Pfizer. Albert Bourla took to the media and said that it may be required to get a third dose of the vaccine at some point after the first two, roughly six to 12 months after, and a annual revaccination to follow that. The third shot- a booster- could have the ability to protect people from new variants like the ones that have emerged in South Africa and the United Kingdom.

As of a couple days ago over 75 million people had been fully vaccinated, however about 5,800 have gotten COVID-19 post-vaccination anyways. That’s still a fairly small amount, and most of these cases have been minor, not requiring hospitalization. Vaccinations are still on the rise and even more people can receive them now through primary care doctors, and even some local pharmacies.